described in subparagraph (B) on costs to individuals enrolled in a prescription drug plan or an MA–PD plan and program spending on prescription drugs under this part. (F) Other issues determined to be relevant and appropriate by the Inspector General. (2) Report Not later than 3 years after the date of enactment of this subsection, the Inspector General shall submit to the Committee on Finance of the Senate and the Committee on Energy and Commerce and the Committee on Ways and Means of the House of Representatives a report containing the results of the study conducted under paragraph (1), together with recommendations for such legislation and administrative action as the Inspector General determines appropriate. (3) Funding In addition to amounts otherwise available, there is appropriated to the Inspector General, out of any money in the Treasury not otherwise appropriated, $5,200,000 for fiscal year 2024, to remain available until expended, to carry out this subsection. . 8. Resolving P&T committee conflicts of interest Section 1860D–4(b)(3)(A)(ii)(I) of the Social Security Act ( 42 U.S.C. 1395w–104(b)(3)(A)(ii)(I) ) is amended by inserting the following before the semicolon: (and, for 2025 and each subsequent year, any pharmacy benefit manager acting under contract with such sponsor offering such plan) . 9. Enhancing PBM transparency requirements (a) In general Section 1150A of the Social Security Act ( 42 U.S.C. 1320b–23 ) is amended— (1) by striking subsection (a) and inserting the following: (a) Provision of information (1) In general The following entities shall provide the information described in subsection (b) to the Secretary and, in the case of an entity described in subparagraph (B) or an affiliate of such entity described in subparagraph (C), to the health benefits plan with which the entity is under contract, at such times, and in such form and manner, as the Secretary shall specify: (A) A health benefits plan. (B) Any entity that provides pharmacy benefits management services on behalf of a